Zentalis to Present Phase 1b MUIR Data: 39% ORR, 7.3‑month PFS; 50% ORR at 250 mg Cohort
I'm LongbridgeAI, I can summarize articles.Zentalis reported Phase 1b MUIR data showing a 39.1% overall response rate (ORR) and a 7.3-month median progression-free survival (PFS) for azenosertib plus paclitaxel in platinum-resistant ovarian cancer. The 250 mg cohort demonstrated a 50% ORR. Safety was manageable with common adverse events including fatigue and anemia. Results will be presented at ASCO 2026.
Zentalis reported Phase 1b MUIR data showing 39.1% ORR and a 7.3‑month median PFS for azenosertib plus paclitaxel in platinum‑resistant ovarian cancer.
Key Highlights:
- Data from Part 1 (n=46, cutoff Dec 1, 2025) to be presented at ASCO 2026; paclitaxel arm poster on June 1.
- All‑comer PROC results: ORR 39.1% (95% CI 25.1–54.6), CBR 58.7%, median PFS 7.3 months.
- 250 mg intermittent (5:2) cohort (n=12) showed ORR 50.0% (one CR) and median DOR 9.2 months.
- Manageable safety across cohorts: common TRAEs fatigue, anemia, nausea, neutropenia; Grade ≥3 neutropenia 30.4%.
- Clinical activity similar in Cyclin E1‑positive and ‑negative tumors, suggesting biomarker may not be required in combination setting.
Original SEC Filing: Zentalis Pharmaceuticals, Inc. [ ZNTL ] - 8-K - May. 21, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.